Literature DB >> 8733512

Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis.

M H Zhao1, D R Jayne, L G Ardiles, F Culley, M E Hodson, C M Lockwood.   

Abstract

Cystic fibrosis (CF), a genetic disorder, is characterized by chronic pulmonary infection/inflammation which leads to respiratory failure. The presence of anti-neutrophil cytoplasmic autoantibodies (ANCA) has previously been observed in the sera of patients with CF. In view of the known relationship of ANCA with primary vasculitis and of their putative pathogenetic role in these disorders, we studied the presence, specificity and isotype of ANCA and their clinical associations in 66 adult CF patients. None of the 66 CF samples had autoantibodies to the major ANCA antigens, proteinase 3 or myeloperoxidase. However, 60/66 (91%) CF samples contained IgG, and 55/66 (83%) IgA, autoantibodies to bactericidal/permeability-increasing protein (BPI), a recently-characterized ANCA specificity. All the IgA anti-BPI-positive samples were also IgG anti-BPI-positive. The autoantibody specificity was confirmed by inhibition assay and immunoblotting of CF sera against a neutrophil granule preparation. Furthermore, in this cross-sectional study, anti-BPI levels were inversely correlated with the observed reductions in FEV1 and FVC (IgA anti-BPI &amp; FEV1: r = -0.508, p < 0.0001), and both IgG and IgA anti-BPI levels were higher in CF patients with secondary vasculitis (n = 6) than in those without (p < 0.05). ANCA with specificity for BPI were present in the majority of CF sera in this study and autoimmune processes may be associated with the development of pulmonary injury in CF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8733512     DOI: 10.1093/qjmed/89.4.259

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  24 in total

Review 1.  Clinical value of antineutrophil cytoplasmic antibodies.

Authors:  V Rus; B S Handwerger
Journal:  Curr Rheumatol Rep       Date:  2000-10       Impact factor: 4.592

Review 2.  A neutrophil-derived anti-infective molecule: bactericidal/permeability-increasing protein.

Authors:  O Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

Review 3.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

Review 4.  Churg-Strauss syndrome.

Authors:  M Conron; H L Beynon
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

5.  [Bactericidal permeability increasing protein (BPI-ANCA marked chronic inflammatory bowel diseases and hepatobiliary diseases].

Authors:  A Schnabel; E Csernok; H Schultz; M Stoffel; C Herzberg; S F Carroll; W L Gross
Journal:  Med Klin (Munich)       Date:  1997-07-15

Review 6.  The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease.

Authors:  Hendrik Schultz; Jerrold P Weiss
Journal:  Clin Chim Acta       Date:  2007-07-13       Impact factor: 3.786

Review 7.  Microscopic polyangiitis.

Authors:  Sharon A Chung; Philip Seo
Journal:  Rheum Dis Clin North Am       Date:  2010-06-11       Impact factor: 2.670

8.  Antineutrophil cytoplasm autoantibodies against bactericidal/permeability-increasing protein in inflammatory bowel disease.

Authors:  R S Walmsley; M H Zhao; M I Hamilton; A Brownlee; P Chapman; R E Pounder; A J Wakefield; C M Lockwood
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

9.  Autoimmunity to polymorphonuclears: functional consequences of the binding of antibodies to membrane and cytoplasmic target antigens of polymorphonuclear leukocytes.

Authors:  J Bartůnková; A Araujo; O Hrusák; A Sedivá
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

10.  BPI-ANCA in transporter associated with antigen presentation (TAP) deficiency: possible role in susceptibility to Gram-negative bacterial infections.

Authors:  H Schultz; S Schinke; J Weiss; V Cerundolo; W L Gross; S Gadola
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.